CytoSorbents Featured in MedCity News

                    CytoSorbents Featured in MedCity News

PR Newswire


MONMOUTH JUNCTION, N.J., May 29, 2013 /PRNewswire/ --CytoSorbents Corporation
(OTCBB: CTSO), a critical care focused company using blood purification to
treat life-threatening illnesses in the intensive care unit, was recently
featured in the article "Blood Purification Device for ICU Patients Seeks to
Treat Root Cause of Sepsis" on May 24, 2013 in MedCity News.

Highlights from the MedCity News Article:

  oThe cost of treating sepsis was $14.6 billion in 2008, according to the
    Centers for Disease Control and Prevention.
  oCytoSorb®, the Company's flagship blood purification technology, targets
    the prevention or treatment of organ failure, the root cause of death in
    sepsis and many other critical illnesses commonly treated in the intensive
    care unit (ICU).
  oOrgan failure is caused by an excessive immune response to an infection or
    injury. CytoSorb® works by directly removing cytokines, toxins, and other
    inflammatory substances that are driving this response.
  oCytoSorb® is approved in all countries of the European Union and is now
    generating commercial sales in Germany, Austria, Switzerland and the
    United Kingdom.
  oCytoSorb® can be used "on-label" in critically-ill patients for many
    medical issues, including sepsis, pancreatitis, liver failure and
    complications of surgery.
  oThe Company plans to pursue a sepsis pivotal trial in the U.S. in early
    2014, with the goal of achieving U.S. regulatory approval for CytoSorb®
    after several years.
  oHighlights approximately $5 million in grant money awarded to the Company
    by agencies of the U.S. Department of Defense such as DARPA and the U.S.

The full article can be found at

About CytoSorbents
CytoSorbents Corporation is a critical care focused therapeutic device company
using blood purification to modulate the immune system and fight multiple
organ failure in life-threatening illnesses. Its purification technology is
based on biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture and
adsorption. CytoSorb®, the Company's flagship product, is approved in the
European Union as a safe and effective extracorporeal cytokine filter,
designed to reduce the "cytokine storm" that could otherwise cause massive
inflammation, organ failure and death in common critical illnesses such as
sepsis, burn injury, trauma, lung injury, and pancreatitis. These are
conditions where the mortality is extremely high, yet no effective treatments
exist. CytoSorbents has numerous products under development based upon the
same underlying blood purification technology such as HemoDefend™,
ContrastSorb, DrugSorb, and others. Additional information is available for
download on the Company's website:

Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for
the safe harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Forward-looking statements in this press
release are not promises or guarantees and are subject to risks and
uncertainties that could cause our actual results to differ materially from
those anticipated. These statements are based on management's current
expectations and assumptions and are naturally subject to uncertainty and
changes in circumstances. We caution you not to place undue reliance upon any
such forward-looking statements. Actual results may differ materially from
those expressed or implied by the statements herein. CytoSorbents Corporation
and CytoSorbents, Inc believe that its primary risk factors include, but are
not limited to: obtaining government regulatory approvals; ability to
successfully develop commercial operations; dependence on key personnel;
acceptance of the Company's medical devices in the marketplace; the outcome of
potential litigation; compliance with governmental regulations; reliance on
research and testing facilities of various universities and institutions; the
ability to obtain adequate and timely financing in the future when needed;
product liability risks; limited manufacturing experience; limited marketing,
sales and distribution experience; market acceptance of the Company's
products; competition; unexpected changes in technologies and technological
advances; and other factors detailed in the Company's Form 10-K filed with the
SEC on April 3, 2013, which is available at

Company Contact:
CytoSorbents Corporation
Dr. Phillip Chan
Chief Executive Officer
(732) 329-8885 ext. *823

Investor Contact:
Alliance Advisors, LLC
Alan Sheinwald
(914) 669-0222

Valter Pinto
(914) 669-0222 x201

Media Contact:
JQA Partners
Jules Abraham
(917) 885-7378

SOURCE CytoSorbents Corporation

Press spacebar to pause and continue. Press esc to stop.